Claims for Patent: 8,431,156

Summary for Patent: 8,431,156

Title:	Pharmaceutical composition
Abstract:	The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.
Inventor(s):	Zala; Yashoraj Rupsinh (Mumbai, IN), Dharmadhikari; Nitin Bhalachandra (Mumbai, IN)
Assignee:	Sun Pharma Advanced Research Company Ltd. (Mumbai, IN)
Application Number:	11/884,770
Patent Claims:	1. An oral controlled release tablet comprising a) a core comprising a first layer comprising one or more swellable agents and a second layer comprising a therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative and one or more pharmaceutically acceptable excipients; b) an active ingredient impermeable coating covering one or more surfaces but not all surfaces of the core, wherein the active ingredient impermeable coating allows permeation of water after contact with an aqueous environment causing the first layer to swell and exert pressure on the impermeable coating, thereby rupturing the coating only on the side that has the swellable agent. 2. The oral controlled release tablet as claimed in claim 1, wherein at least one pharmaceutically acceptable excipient in the second layer is a rate-controlling agent. 3. The oral controlled release tablet as claimed in claim 2, wherein the rate-controlling agent is in admixture with the active ingredient. 4. The oral controlled release tablet as claimed in claim 3, wherein the rate controlling agent is selected from the group consisting of water- soluble hydrophilic polymers, water-insoluble hydrophobic polymers, hydrophobic excipients and mixtures thereof. 5. The oral controlled release tablet as claimed in claim 4, wherein the water soluble hydrophilic polymer is selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate copolymers, polysaccharides, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives and mixtures thereof. 6. The oral controlled release tablet as claimed in claim 4, wherein the water-insoluble hydrophobic polymer is selected from the group consisting of acrylates, cellulose derivatives such as ethylcellulose or cellulose acetate, methacrylates, acrylic acid copolymers and high molecular weight polyvinylalcohols and mixtures thereof. 7. The oral controlled release tablet as claimed in claim 4, wherein the hydrophobic excipient is selected from the group consisting of a natural fat, beeswax, polyethoxylated beeswax, a mono-, bi- or tri-substituted glyceride, glycerylpalmitostearate, glycerylbehenate, diethyleneglycolpalmitostearate, a polyethyleneglycol stearate, a polyoxyethyleneglycolpalmitostearate, glycerylmonopalmitostearate, cetylpalmitate, polyethyleneglycolpalmitostearate, mono- or di-glycerylbehenate, a fatty alcohol associated with a polyethoxylate fatty alcohol, cetyl alcohol, stearic acid, a saturated or unsaturated fatty acid or a hydrogenated derivative thereof, and hydrogenated castor oil and mixtures thereof. 8. The oral controlled release tablet as claimed in claim 4, wherein the rate controlling agent is used in an amount ranging from 1 to 50% by weight of the tablet. 9. The oral controlled release tablet as claimed in claim 1, wherein the swellable agent is selected from the group consisting of a swellable excipient, a gas generating agent and mixtures thereof. 10. The oral controlled release tablet as claimed in claim 9, wherein the swellable excipient is selected from the group consisting of crospovidone; cellulose and cellulose derivatives, cros slinkedcarboxyalkylcelluloses and their alkali salts; sodium starch glycolate, starch and starch derivatives, resins and mixtures thereof. 11. The oral controlled release tablets as claimed in claim 9, wherein the swellable agent is present in an amount of about 0.5% to about 95% by weight of the swellable composition. 12. The oral controlled release tablet as claimed in claim 9, wherein the gas generating agent is selected from a group consisting of calcium carbonate, sodium bicarbonate, potassium bicarbonate, sodium sulfite, sodium bisulfite, sodium metabisulfite, and mixtures thereof. 13. The oral controlled release tablet as claimed in claim 1, wherein the active ingredient impermeable coating comprises a film former selected from the group consisting of cellulose derivatives, ethyl cellulose, polyvinyl esters, polyvinyl acetals, polyacrylic acid esters, butadiene styrene copolymers, methacrylic and acrylate polymers, and mixtures thereof. 14. The oral controlled release tablet as claimed in claim 1, wherein the core is coated to a weight gain of about 8% to about 15%. 15. The oral controlled release tablet as claimed in claim 1, wherein the coating has a passageway.